TAZORAC ®, Acne treatment, Acne medicine, Acne solution, Acne medication, Adult acne, Teen acne

2007 Professional Events Calendar

Month Meeting Dates Location
January Caribbean Dermatology January 15-19 St. Thomas, VI
  Orlando Dermatology January 18-20 Orlando, FL
February American Academy of Dermatology Winter Meeting February 1-5 San Antonio, TX
March Hawaii Dermatology March 1-7 Waikoloa, HI
  AOCD Mid-Year Meeting March 12-15 Monterey, CA
  Winter Clinical March 14-18 Maui, HI
April Derm Foundation April 2-6 Amelia Island, FL
May      
June Alabama Derm June 28-30 Sandestin, FL
July Alabama Derm July 1 Sandestin, FL
  American Academy of Dermatology Summer Meeting July 30-31 Chicago, IL
August American Academy of Dermatology Summer Meeting August 1-3 Chicago, IL
September      
October Fall Clinical October 18-21 Las Vegas, NV
  AOCD Annual Meeting October 26-30 Las Vegas, NV
November SDPA November 4-8 Tampa Bay, FL
December      
bevel
img img img
 

TAZORAC® (tazarotene) Cream 0.1% is indicated for acne vulgaris.
TAZORAC® (tazarotene) Gel 0.1% is indicated for mild to moderate facial acne vulgaris.

Important Safety Information

Contraindications

Retinoids may cause fetal harm when administered to a pregnant woman.

TAZORAC® Cream and Gel 0.1% are contraindicated in women who are or may become pregnant. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, treatment should be discontinued and the patient apprised of the potential hazard to the fetus.

Warnings

Women of child-bearing potential should be warned of the potential risk and use adequate birth-control measures when TAZORAC® Cream or Gel 0.1% is used.

Precautions

Retinoids should not be used on eczematous skin, as they may cause severe irritation.

TAZORAC® Cream or Gel 0.1% should be administered with caution if the patient is also taking drugs known to be photosensitizers (e.g., thiazides, tetracyclines, fluoroquinolones, phenothiazines, sulfonamides) because of the increased possibility of augmented photosensitivity.

Adverse Reactions

The most frequent adverse reactions reported during clinical trials with TAZORAC® Cream 0.1% in the treatment of acne occurring in 10% to 30% of patients, in descending order, included desquamation, dry skin, erythema, and burning sensation.

The most frequent adverse events reported with TAZORAC® Gel 0.1% in the treatment of acne occurring in 10% to 30% of patients, in descending order, included desquamation, burning/stinging, dry skin, erythema, and pruritus.

Please click here for full prescribing information for TAZORAC® Cream and Gel 0.1%.

  
img img img